<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03753555</url>
  </required_header>
  <id_info>
    <org_study_id>k（2018）44</org_study_id>
    <nct_id>NCT03753555</nct_id>
  </id_info>
  <brief_title>The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques</brief_title>
  <acronym>INSIST-HRMRI</acronym>
  <official_title>The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques: a Prospective, Random, Single-center Study Based on High Resolution Magnetic Resonance Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Shenyang Military Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Shenyang Military Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intracranial atherosclerotic disease is the most common cause of ischemic stroke that is
      directly attributed to the progression or rupture of intracranial high-risk plaque in Asia.
      Many studies mainly from Euro-American population with a focus on extracranial carotid plaque
      have fully demonstrated the advantages of intensive statin therapy on stabilizing or
      reversing plaque burden, reversing plaque composition presenting that lipid-rich necrotic
      core (LRNC) is gradually replaced by fibrous tissue, and even reversing pattern of arterial
      remodeling to reduce the occurrence of cerebrovascular events. Yet, direct evidence of the
      effect of intensive statin therapy on intracranial atherosclerotic plaques is lacking and the
      effect of statin intensity and duration on intracranial plaque burden and composition is
      still unclear. High resolution magnetic resonance imaging (HRMRI) is a new and non-invasive
      technique that enable to assess the morphologic characteristics of vascular wall and plaque
      composition of intracranial artery. Based on above discussion, the investigators conduct this
      study to further determine the effect of intensive statin in ischemic stroke with
      intracranial atherosclerotic plaques.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in remodeling index after the statin treatment</measure>
    <time_frame>baseline, 6 months, 12 months after treatment</time_frame>
    <description>remodeling index: crimed vessel area/normal vessel area on high-resolution MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in plaque burden after the statin treatment</measure>
    <time_frame>baseline, 6 months, 12 months after treatment</time_frame>
    <description>plaque burden: crimed vessel wall area/crimed vessel area on high-resolution MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes plaque composition in after the statin treatment</measure>
    <time_frame>baseline, 6 months, 12 months after treatment</time_frame>
    <description>plaque composition: lipid core and fiber tissue of plaque on high-resolution MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>level of serum bio-markers compared with baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Serum level of LDL、hs-CRP、sLOX1 and oxLDL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of serum bio-markers compared with baseline</measure>
    <time_frame>12 months</time_frame>
    <description>Serum level of LDL、hs-CRP、sLOX1 and oxLDL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRS (0-2)</measure>
    <time_frame>6 months</time_frame>
    <description>proportion of mRS (0-2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRS (0-2)</measure>
    <time_frame>12 months</time_frame>
    <description>proportion of mRS (0-2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vascular events</measure>
    <time_frame>6 months</time_frame>
    <description>incidence of Transient ischemic attack, stroke or other vascular events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vascular events</measure>
    <time_frame>12 months</time_frame>
    <description>incidence of Transient ischemic attack, stroke or other vascular events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>abnormal test data</measure>
    <time_frame>12 months</time_frame>
    <description>incidence of abnormal liver function or muscle enzyme levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>any adverse event</measure>
    <time_frame>12 months</time_frame>
    <description>incidence of adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death of any causes</measure>
    <time_frame>12months</time_frame>
    <description>proportion of death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Stroke, Ischemic</condition>
  <condition>Atherosclerosis, Cerebral</condition>
  <arm_group>
    <arm_group_label>Routine-dose statin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Routine-dose statin group will be gaven the treatment of atorvastatin 20mg Qd for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high-dose statin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high-dose statin group will be gaven the treatment of atorvastatin 40-80mg Qd till 6 months at the moment the subjects will be followed up to determine plaques status by HRMRI examination, among which the subjects presenting culprit plaque progression with the significant increasing of plaque burden including intraplaque hemorrhage will be again randomized into two groups at a ratio of 1:1 as followed: atorvastatin-probucol group will be administrated atorvastatin 40-80mg Qd plus probucol 0.5g Bid till 12 months, the other group will maintain the original scheme till 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin Calcium</intervention_name>
    <description>20mg Qd for 12 months</description>
    <arm_group_label>Routine-dose statin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin Calcium</intervention_name>
    <description>40-80mg Qd for 6 months</description>
    <arm_group_label>high-dose statin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probucol</intervention_name>
    <description>0.5g Bid for 6 months</description>
    <arm_group_label>high-dose statin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient age between 18-80 years

          2. Time of onset: within 1 week

          3. NIHSS score ≤12

          4. Acute ischemic stroke confirmed by head CT or MRI

          5. Premorbid mRS ≤1

          6. The degree of stenosis of carotid artery, vertebral artery and intracranial portion of
             internal carotid artery on the lesion side ＜50%

          7. The culprit plaque or possible culprit plaque with plaque burden of 40% or more found
             by HRMRI in the proximal part of the middle cerebral artery M1 segment or basilar
             artery of ipsilateral lesion

          8. Signed informed consent

        Exclusion Criteria:

          1. Intracranial hemorrhage found by head CT

          2. Stroke attributable to cardioembolic origin (atrial fibrillation, valvular heart
             disease, aortic arch atherosclerosis)

          3. Severe hepatic or renal dysfunction

          4. Pregnant females

          5. Abnormal elevation of creatine phosphokinase

          6. Expected stent angioplasty

          7. Blood sugar is out of control

          8. Receiving statins within 1 month before onset

          9. Obstinate hypertension with more than 140/90 mmHg after medication

         10. Not willing and able to comply with scheduled visits, lifestyle guidelines, treatment
             plan, laboratory tests, and other study procedures

         11. Unsuitable for this clinical studies assessed by researcher
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huisheng Chen, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Neurology Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xinhong Wang, Doctor</last_name>
    <phone>15309885658</phone>
    <phone_ext>024-28897512</phone_ext>
    <email>450341972@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yu Cui, Master</last_name>
    <phone>18842398646</phone>
    <phone_ext>024-28897512</phone_ext>
    <email>314486939@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>General Hospital of ShenYang Military Region</name>
      <address>
        <city>ShenYang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng Xia, Ph.D</last_name>
      <email>xiacheng1975@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 13, 2018</study_first_submitted>
  <study_first_submitted_qc>November 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2018</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital of Shenyang Military Region</investigator_affiliation>
    <investigator_full_name>Hui-Sheng Chen</investigator_full_name>
    <investigator_title>Department Chairman</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Intracranial Arteriosclerosis</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Probucol</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

